| Kelli Airey, RN | |
|
113 Crosby Rd Ste 1, Dover, NH 03820-4370 | |
| (603) 516-9300 | |
| (603) 740-9179 |
| Full Name | Kelli Airey |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 113 Crosby Rd Ste 1, Dover, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952040248 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 070192-21 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kelli Airey, RN 113 Crosby Rd Ste 1, Dover, NH 03820-4370 Ph: (603) 516-9300 | Kelli Airey, RN 113 Crosby Rd Ste 1, Dover, NH 03820-4370 Ph: (603) 516-9300 |
News Archive
The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
A new study has tried to assess the genetic variants among mosquitoes that make them more susceptible to spreading deadly viral diseases such as dengue, yellow fever, Zika and chikungunya and more resistant to insecticides that are used to kill them.
Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.
› Verified 4 days ago
Sadie Irving, APRN Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 15 Old Rollinsford Rd Ste 302, Dover, NH 03820 Phone: 603-742-9200 | |
Karla M Deinstadt, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-740-4478 Fax: 603-740-2244 | |
Martha King, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 113 Crosby Rd Ste 1, Dover, NH 03820 Phone: 603-516-9300 Fax: 603-740-9179 | |
Kirstin Sylvester, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 113 Crosby Rd Ste 1, Dover, NH 03820 Phone: 603-516-9300 Fax: 603-740-9179 | |
Sarah Corinne Suri, CRNA Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-609-6819 Fax: 603-609-6821 | |
Ann West, RN, CDE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-742-5252 Fax: 603-740-2244 | |
Ingrid Offenbacher Surkan, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 584 Central Ave, Dover, NH 03820 Phone: 404-200-0462 |